# Yuan-Pin Hung

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7663095/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 51 papers | 1,031 citations | 448610 19 h-index | 536525 29 g-index |
| 52 all docs | 52 docs citations | 52 times ranked | 1413 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Risk of non-typhoidal Salmonella vascular infections is increased with degree of atherosclerosis and inflammation: A multicenter study in southern Taiwan. Journal of Microbiology, Immunology and Infection, 2022, 55, 474-481. | 1.5 | 4 |
| 2 | The emergence of Clostridioides difficile PCR ribotype 127 at a hospital in northeastern Taiwan. Journal of Microbiology, Immunology and Infection, 2022, 55, 896-909. | 1.5 | 2 |
| 3 | Effect of Doxycycline in Decreasing the Severity of Clostridioides difficile Infection in Mice. Antibiotics, 2022, 11, 116. | 1.5 | 0 |
| 4 | Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?. Antibiotics, 2022, 11, 220. | 1.5 | 66 |
| 5 | Neutrophil Ratio of White Blood Cells as a Prognostic Predictor of Clostridioides difficile Infection. Journal of Inflammation Research, 2022, Volume 15, 1943-1951. | 1.6 | 3 |
| 6 | Severe Clostridium difficile infections in intensive care units: Diverse clinical presentations. Journal of Microbiology, Immunology and Infection, 2021, 54, 1111-1117. | 1.5 | 18 |
| 7 | Risk factors of Clostridium difficile-associated diarrhea in hospitalized adults: Vary by hospitalized duration. Journal of Microbiology, Immunology and Infection, 2021, 54, 276-283. | 1.5 | 26 |
| 8 | Clostridioides difficile infection in patients with hematological malignancy: A multicenter study in Taiwan. Journal of Microbiology, Immunology and Infection, 2021, 54, 1101-1110. | 1.5 | 13 |
| 9 | Clinical Impact and Risk Factors of Nonsusceptibility to Third-Generation Cephalosporins Among Hospitalized Adults with Monomicrobial Enterobacteriaceae Bacteremia in Southern Taiwan: A Multicenter Study. Infection and Drug Resistance, 2021, Volume 14, 689-697. | 1.1 | 1 |
| 10 | Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents. Pathogens, 2021, 10, 649. | 1.2 | 10 |
| 11 | Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?. Journal of Microbiology, Immunology and Infection, 2021, 54, 1011-1017. | 1.5 | 9 |
| 12 | Risk factors and clinical impact of bacteremia due to carbapenem-nonsusceptible Enterobacteriaceae: A multicenter study in southern Taiwan. Journal of Microbiology, Immunology and Infection, 2021, 54, 1122-1129. | 1.5 | 6 |
| 13 | Gut Dysbiosis during COVID-19 and Potential Effect of Probiotics. Microorganisms, 2021, 9, 1605. | 1.6 | 30 |
| 14 | The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients. Frontiers in Immunology, 2021, 12, 691039. | 2.2 | 9 |
| 15 | Clostridioides difficile infection: an emerging zoonosis?. Expert Review of Anti-Infective Therapy, 2021, 19, 1543-1552. | 2.0 | 6 |
| 16 | The Potential of Probiotics to Eradicate Gut Carriage of Pathogenic or Antimicrobial-Resistant Enterobacterales. Antibiotics, 2021, 10, 1086. | 1.5 | 5 |
| 17 | Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection. Microbiology Spectrum, 2021, 9, e0079921. | 1.2 | 6 |
| 18 | Advances in the Application of Nanomaterials as Treatments for Bacterial Infectious Diseases. Pharmaceutics, 2021, 13, 1913. | 2.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clostridium butyricum therapy for mild-moderate Clostridioides difficile infection and the impact of diabetes mellitus. Bioscience of Microbiota, Food and Health, 2021, 41, 37-44. | 0.8 | 2 |
| 20 | Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerging Microbes and Infections, 2020, 9, 2157-2168. | 3.0 | 38 |
| 21 | Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation. Journal of Microbiology, Immunology and Infection, 2019, 52, 841-850. | 1.5 | 15 |
| 22 | Bloodstream infections in hospitalized adults with dengue fever: Clinical characteristics and recommended empirical therapy. Journal of Microbiology, Immunology and Infection, 2019, 52, 225-232. | 1.5 | 16 |
| 23 | Community-onset Clostridium difficile infection at a tertiary medical center in southern Taiwan, 2007â€“2015. Journal of Microbiology, Immunology and Infection, 2018, 51, 243-250. | 1.5 | 13 |
| 24 | Clinical Impact of Sequence Type 131 in Adults with Community-Onset Monomicrobial Escherichia Coli Bacteremia. Journal of Clinical Medicine, 2018, 7, 508. | 1.0 | 5 |
| 25 | Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic <em>Clostridium difficile</em> isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan. Infection and Drug Resistance, 2018, Volume 11, 1197-1203. | 1.1 | 21 |
| 26 | Comparing the therapeutic efficacies of third-generation cephalosporins and broader-spectrum Î²-lactams as appropriate empirical therapy in adults with community-onset monomicrobial Enterobacteriaceae bacteraemia: a propensity score matched analysis. International Journal of Antimicrobial Agents, 2017, 49, 617-623. | 1.1 | 9 |
| 27 | Age-Related Trends in Adults with Community-Onset Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 1.4 | 25 |
| 28 | Perceptions of Clostridium difficile infections among infection control professionals in Taiwan. Journal of Microbiology, Immunology and Infection, 2017, 50, 521-526. | 1.5 | 4 |
| 29 | Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli , Klebsiella species and Proteus mirabilis bacteremia. International Journal of Antimicrobial Agents, 2017, 50, 371-376. | 1.1 | 12 |
| 30 | Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 1.4 | 22 |
| 31 | Lauric Acid Is an Inhibitor of Clostridium difficile Growth in Vitro and Reduces Inflammation in a Mouse Infection Model. Frontiers in Microbiology, 2017, 8, 2635. | 1.5 | 61 |
| 32 | Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset Escherichia coli , Klebsiella spp. and Proteus mirabilis bacteraemia. International Journal of Antimicrobial Agents, 2016, 48, 712-718. | 1.1 | 14 |
| 33 | Zoonotic potential of the Clostridium difficile RT078 family in Taiwan. Anaerobe, 2016, 41, 125-130. | 1.0 | 19 |
| 34 | Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents. Journal of Microbiology, Immunology and Infection, 2016, 49, 584-590. | 1.5 | 10 |
| 35 | Predominance of Clostridium difficile Ribotypes 017 and 078 among Toxigenic Clinical Isolates in Southern Taiwan. PLoS ONE, 2016, 11, e0166159. | 1.1 | 28 |
| 36 | Proton-Pump Inhibitor Exposure AggravatesClostridium difficileâ€“Associated Colitis: Evidence From a Mouse Model. Journal of Infectious Diseases, 2015, 212, 654-663. | 1.9 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The first case of severe Clostridium difficile ribotype 027 infection in Taiwan. Journal of Infection, 2015, 70, 98-101. | 1.7 | 22 |
| 38 | Clinical impact of Clostridium difficile colonization. Journal of Microbiology, Immunology and Infection, 2015, 48, 241-248. | 1.5 | 58 |
| 39 | Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. Journal of Microbiology, Immunology and Infection, 2015, 48, 183-189. | 1.5 | 40 |
| 40 | Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections. Journal of Microbiology, Immunology and Infection, 2014, 47, 197-203. | 1.5 | 34 |
| 41 | Clostridium difficile ribotype 126 in southern Taiwan: A cluster of three symptomatic cases. Anaerobe, 2014, 30, 188-192. | 1.0 | 24 |
| 42 | Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection. Anaerobe, 2014, 30, 24-26. | 1.0 | 15 |
| 43 | Incidence of Aeromonas bacteremia in southern Taiwan: Vibrio and Salmonella bacteremia as comparators. Journal of Microbiology, Immunology and Infection, 2014, 47, 145-148. | 1.5 | 37 |
| 44 | Cytomegalovirus disease in nonimmunocompromised, human immunodeficiency virus-negative adults with chronic kidney disease. Journal of Microbiology, Immunology and Infection, 2014, 47, 345-349. | 1.5 | 51 |
| 45 | Risk Factors of Fecal Toxigenic or Non-Toxigenic Clostridium difficile Colonization: Impact of Toll-Like Receptor Polymorphisms and Prior Antibiotic Exposure. PLoS ONE, 2013, 8, e69577. | 1.1 | 45 |
| 46 | Effects of PPARÎ³ and RBP4 Gene Variants on Metabolic Syndrome in HIV-Infected Patients with Anti-Retroviral Therapy. PLoS ONE, 2012, 7, e49102. | 1.1 | 9 |
| 47 | Impact of Toxigenic Clostridium difficile Colonization and Infection among Hospitalized Adults at a District Hospital in Southern Taiwan. PLoS ONE, 2012, 7, e42415. | 1.1 | 49 |
| 48 | Comparisons of Clinical Characters in Patients with Pneumococcal and Legionella Pneumonia. Journal of Microbiology, Immunology and Infection, 2010, 43, 215-221. | 1.5 | 7 |
| 49 | Clostridium difficile Infection at a Medical Center in Southern Taiwan: Incidence, Clinical Features and Prognosis. Journal of Microbiology, Immunology and Infection, 2010, 43, 119-125. | 1.5 | 43 |
| 50 | Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: A retrospective chart review. Clinical Therapeutics, 2009, 31, 1977-1986. | 1.1 | 19 |
| 51 | Prognostic Effects of Delayed Administration of Appropriate Antimicrobials in Bacteraemic Adults Initially Presenting with Various Body Temperatures. Infection and Drug Resistance, 0, Volume 15, 3149-3160. | 1.1 | 0 |